Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

Phase 1 Completed 43 enrolled Taris Biomedical LLC

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.

Timeline

Start: 2017-04-04
Primary completion: 2019-09-27
Completion: 2019-09-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trospium	Small molecule	—	Other

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

Summary

Timeline

Drugs

Indications